Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway(Providence College), H. Robert Brashear(Janssen (United States)), Lawrence S. Honig(Columbia University), Julia Lull(Janssen (United States)), Enchi Liu(University of Washington), Michael Grundman(University of San Diego), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit), Marcel Reichert(Veterans Health Administration), Kaj Blennow(Sahlgrenska University Hospital), Anton P. Porsteinsson(University of Rochester), William E. Klunk(University of Pittsburgh), Eric Yuen(Janssen (United States)), Iulia Cristina Tudor(Janssen (United States)), Murray A. Raskind(University of Washington), Nzeera Ketter(Janssen (United States)), Maja Miloslavsky(Janssen (United States)), Bijan Nejadnik(Janssen (United States)), Daniel Wang(Vanderbilt University Medical Center), Yuan Lü(Jazz Pharmaceuticals (United States)), Marwan N. Sabbagh(Cleveland Clinic), Ronald S. Black(Pfizer (United States)), Reisa A. Sperling(Brigham and Women's Hospital), Volkmar Guenzler(Janssen (United States)), Steven H. Ferris(NYU Langone Health)
New England Journal of Medicine
January 22, 2014
Cited by 1,966


Related Papers